Mitsubishi Tanabe Sees Open Road With Telaprevir Approval And Merck's Boceprevir Discontinued In Japan
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Mitsubishi Tanabe Pharma Corp. received a double dose of good news Sept. 26, leading a list of drugs that received marketing approval from Japan's Ministry of Health, Labor and Welfare with in-licensed protease inhibitor telaprevir and oral multiple sclerosis therapy fingolimod
You may also be interested in...
Mitsubishi Tanabe Gains Premium Prices For Fingolimod And Telaprevir
Japan's Chuikyo rewarded the company with better-than-expected NHI listings, but can Mitsubishi Tanabe's sales force shortages help fill demand?
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services